Piramal Pharma moves to acquire remaining 26% of biologics CDMO Yapan Bio

The proposed purchase would increase Piramal Pharma's ownership of the vaccines and biologics CDMO from 74% to 100%, with final consideration and completion terms still under discussion.
On 18 November 2026, Piramal Pharma disclosed that its authorised board committee had approved exercising a call option to acquire the remaining 26% equity stake in Yapan Bio from existing shareholders.
If completed, the transaction would make Yapan Bio a wholly owned subsidiary of Piramal Pharma, although purchase consideration, definitive transaction terms and the effective share-transfer date have not yet been finalised.
Field | Content |
Alert Type | Deal |
Companies | Piramal Pharma Limited; Yapan Bio Private Limited |
Deal Type | Proposed acquisition of remaining minority equity stake through exercise of call option |
Asset or Company | Remaining 26% equity stake in Yapan Bio Private Limited |
Therapy Area(s) | Vaccines; biologics; biopharmaceutical development and manufacturing |
Technology or Modality | Contract development and manufacturing services including biologics process development, characterisation and Phase I/II GMP manufacturing |
Deal Value | Purchase consideration not disclosed; final acquisition terms and effective transfer date have not been finalised. |
Geography | India |
What Happened | Piramal Pharma's authorised board committee approved exercising a call option to acquire the remaining 26% shareholding in Yapan Bio. The company is discussing the steps required to complete the proposed transaction with existing shareholders. |
Why It Matters | Completion would increase Piramal Pharma's holding in Yapan Bio from 74% to 100%, consolidating ownership of a business providing specialist vaccines and biologics development and manufacturing services. |
Supporting Context | Yapan Bio specialises in process development, characterisation and Phase I/II GMP manufacturing for vaccines and biologics. Piramal Pharma already owns 74% of the company. |
Strategic Rationale | Full ownership would consolidate control of Yapan Bio's specialised biologics CDMO operations within Piramal Pharma, subject to completion of the proposed acquisition. |
Potential Impact | If completed, Yapan Bio would become a wholly owned subsidiary and Piramal Pharma would hold the entire equity interest. Any operational or financial effects beyond this remain unquantified. |
Key Takeaway | Piramal Pharma has approved exercising its option to acquire the remaining 26% of Yapan Bio, but the acquisition has not been completed and financial terms remain outstanding. |
What to Watch | Agreement on purchase consideration, execution of definitive documentation, completion of the share transfer and subsequent stock-exchange disclosures. |
Primary Source | https://nsearchives.nseindia.com/corporate/Priyankamehta_18112026171520_SE_Disclosure_Call_Option_Exercise.pdf |
Relevant Date | 18 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments